Does LENVATINIB Cause Tumour marker increased? 32 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 32 reports of Tumour marker increased have been filed in association with LENVATINIB (Lenvima). This represents 0.1% of all adverse event reports for LENVATINIB.
32
Reports of Tumour marker increased with LENVATINIB
0.1%
of all LENVATINIB reports
0
Deaths
17
Hospitalizations
How Dangerous Is Tumour marker increased From LENVATINIB?
Of the 32 reports, 17 (53.1%) required hospitalization.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENVATINIB. However, 32 reports have been filed with the FAERS database.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Malignant neoplasm progression (2,929)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
ELACESTRANT (222)
OLAPARIB (171)
Which LENVATINIB Alternatives Have Lower Tumour marker increased Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE